{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["332(7)"],"submitter":["HARMONi-A Study Investigators"],"pubmed_abstract":["<h4>Importance</h4>For patients with non-small cell lung cancer whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, particularly third-generation TKIs, optimal treatment options remain limited.<h4>Objective</h4>To compare the efficacy of ivonescimab plus chemotherapy with chemotherapy alone for patients with relapsed advanced or metastatic non-small cell lung cancer with the epidermal growth factor receptor (EGFR) variant.<h4>Design, setting, and participants</h4>Double-blind, placebo-controlled, randomized, phase 3 trial at 55 sites in China enrolled participants from January 2022 to November 2022; a total of 322 eligible patients were enrolled.<h4>Interventions</h4>Participants received ivonescimab (n = 161) or placebo (n = 161) plus pemetrexed and"],"journal":["JAMA"],"pagination":["561-570"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11337070"],"repository":["biostudies-literature"],"pubmed_title":["Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial."],"pmcid":["PMC11337070"],"pubmed_authors":["Hu Y","Liang W","Dong X","Huang J","Guo Y","Du X","Wu D","Zhang L","Su H","Guo J","Xia M","Chen Y","Wang Y","Wang Z","Yang H","Yang L","Yang K","Chen L","He M","Lu D","Xu F","Chen H","Li K","Sun Y","Li M","Li W","Li X","Feng J","He Z","Lu H","HARMONi-A Study Investigators","Lu J","Hu M","Xu S","Feng W","Yang R","Lan H","Liu L","Hou X","Jia L","Zhao Y","Yi T","Cheng Y","Liu X","Wang ZM","Song Q","Jia Y","Li B","Song X","Zhao H","Zhou J","Zhou M","Zhou N","Fan Y","Lv D","Huang Y","Zhang Z","Fang W","Zhang Y","Luo Y","Liu B","Liu C","Peng J"],"additional_accession":[]},"is_claimable":false,"name":"Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.","description":"<h4>Importance</h4>For patients with non-small cell lung cancer whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, particularly third-generation TKIs, optimal treatment options remain limited.<h4>Objective</h4>To compare the efficacy of ivonescimab plus chemotherapy with chemotherapy alone for patients with relapsed advanced or metastatic non-small cell lung cancer with the epidermal growth factor receptor (EGFR) variant.<h4>Design, setting, and participants</h4>Double-blind, placebo-controlled, randomized, phase 3 trial at 55 sites in China enrolled participants from January 2022 to November 2022; a total of 322 eligible patients were enrolled.<h4>Interventions</h4>Participants received ivonescimab (n = 161) or placebo (n = 161) plus pemetrexed and","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-07-15T08:07:11.442Z","creation":"2025-04-06T22:26:00.949Z"},"accession":"S-EPMC11337070","cross_references":{"pubmed":["38820549"],"doi":["10.1001/jama.2024.10613"]}}